openPR Logo
Press release

Pulmonary Arterial Hypertension Market will rise to US$ 5.19 Billion by 2020

05-05-2017 03:14 PM CET | Health & Medicine

Press release from: Transparency Market Research

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH is a very rare condition that occurs when pulmonary arteries become narrow in diameter or get blocked. Based on information gathered from various sources including WHO and CDC, the worldwide prevalence of PAH has been estimated to be between 100,000 – 200,000, approximately 15 - 50 cases per million people. Although, there is no cure for PAH, treatments are available to reduce symptoms, improve the quality of life, and slow down disease progression. Prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), and phosphodiesterase-5 (PDE-5) inhibitors are the most-prescribed drug classes for the treatment of PAH. Recently, a new drug class, soluble guanylate cyclase (sGC) stimulators, has been identified to treat people suffering from PAH.

The recent approval of drugs and the anticipated approval of new PAH drugs in the coming years have been identified as the major growth drivers of the PAH market during the forecast period between 2014 and 2020. Opsumit (macitentan), Orenitram (treprostinil extended release tablet), and Adempas (riociguat) are the PAH drugs that received approval from various regulatory agencies across the world in the recent years (2013 and 2014). A new therapeutic agent Uptravi (selexipag) is anticipated to be introduced in the first half of 2016. In addition, governments of various countries providing incentives to companies engaged in the development and manufacturing of PAH drugs are also expected to contribute to the market growth.

This 73 page report gives readers a comprehensive overview of the Pulmonary Arterial Hypertension Market. Browse through 14 data tables and 22 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

On the other hand, the patent expiry of major PAH drugs such as Tracleer, Letairis, Adcirca, and Tyvaso is expected to affect the market revenue during the forecast period, as their generic versions would be sold at prices 70% to 80% lower than that of the branded ones. Development of breakthrough therapy for the treatment of PAH is expected to be a growth opportunity for drug manufacturers, as the currently available drugs are not enough to meet the medical needs of people suffering from PAH.

The global PAH market has been segmented into prostacyclin and prostacyclin analogs, ERAs, PDE-5 inhibitors, and sGC stimulators, based on the commercially-available drug classes, to treat PAH. Of these, ERAs represented the largest segment in 2013 with a revenue share of 55.8%. However, during the forecast period, the prostacyclin and prostacyclin analogs segment is expected to record the highest growth, mainly due to the approval of Orenitram (treprostinil extended release tablet) in December 2013 and the anticipated approval of Uptravi (selexipag) in the first quarter of 2016. Adempas (riociguat) is the only approved sGC stimulator for the treatment of PAH. Adempas was first approved by the U.S. FDA in October 2013.

Get accurate market forecast and analysis on the Pulmonary Arterial Hypertension Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

In terms of geography, the global pulmonary arterial hypertension (PAH) market has been segmented into four major regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America, with a share of 44.6%, represented the largest regional market for PAH in terms of revenue in 2013, followed by Europe. These two developed regions are expected to witness substantial growth during the forecast period, primarily due to the recently approved PAH drugs in the market and products that are anticipated to receive approval during the next few years. In the Asia Pacific region, Japan, China, India, Australia, and New Zealand exhibit immense opportunities for the companies operating in the PAH market. In RoW, the low level of awareness regarding the diagnosis and treatment of PAH is one of the prime reasons restraining the market growth. However, during the forecast period, growing awareness regarding PAH would drive growth of the market.

Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation are the key players operating in the global PAH market.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Arterial Hypertension Market will rise to US$ 5.19 Billion by 2020 here

News-ID: 525328 • Views: 264

More Releases from Transparency Market Research

Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15

All 5 Releases


More Releases for PAH

Pulmonary Arterial Hypertension (PAH) - Market Outlook and Competitive Landscape …
Report Overview  The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level  Comprehensive insight on patient segmentation has been provided into the epidemiology of the Pulmonary Arterial Hypertension (PAH) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China  Drug utilization and analysis on the current
Pulmonary Arterial Hypertension (PAH) Market – Global Industry Insights, Trend …
Pulmonary hypertension or PH is a condition in which the blood pressure rises in the pulmonary artery, vein, or capillaries (collectively known as lung vasculature), which might lead to shortness of breath, fainting, leg swelling, and dizziness, among others. Pulmonary hypertension may be a relentless disease with a noticeable reduction in exercise tolerance. Pulmonary arterial hypertension or PAH indicates that the patient has high blood pressure in arteries that carry
Pulmonary Arterial Hypertension (PAH) Market Research Report Forecast to 2020
The global PAH market is estimated to reach a valuation of US$5.19 bn by the end of 2020, expanding at a tremendous CAGR of 17.90% between 2014 and 2020. According to the market report, the global PAH market has been evaluated on the basis of drug classes and regional distribution. Prostacyclin, prostacyclin analogs, PDE-5 inhibitors, ERAs, and sGC stimulators are the key drugs available in the global market to treat PAH.
Global Pulmonary Arterial Hypertension (PAH) Market| MarketResearchReports.biz
Latest industry research report on: Global Pulmonary Arterial Hypertension (PAH) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V
Pulmonary Arterial Hypertension (PAH) Market by Key Players 
Global Pulmonary Arterial Hypertension (PAH) Market: Snapshot Pulmonary arterial hypertension (PAH) is a very rare type of progressive disorder related to high blood pressure. However, the rate of incidence of this disorder is gradually gaining traction. Various sources, including WHO and CDC, suggest that the global prevalence of PAH is anticipated to be between 100,000 and 200,000, narrowing down to about 15-50 cases per million heads. There is no permanent cure
Pulmonary Arterial Hypertension (PAH) Market by Key Players 
Global Pulmonary Arterial Hypertension (PAH) Market: Snapshot Pulmonary arterial hypertension (PAH) is a very rare type of progressive disorder related to high blood pressure. However, the rate of incidence of this disorder is gradually gaining traction. Various sources, including WHO and CDC, suggest that the global prevalence of PAH is anticipated to be between 100,000 and 200,000, narrowing down to about 15-50 cases per million heads. There is no permanent cure